Clinical trial for monitoring anti-coagulation in ECMO by anti-Xa activity

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023371

Enrollment

Unknown

Registered

2019-05-25

Start date

2019-06-15

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ECMO patient

Interventions

anti-Xa activity group:anti-Xa activity to monitor heprin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)VVECMO PF 600 mmHg; metabic acidosis,pH 3; (2)VAECMO: cardiac index 20mmHg; urine <20ml/h (with normal kidney function); metabolic acidosis (high lactic acid).

Exclusion criteria

Exclusion criteria: melignant tumor,late stage, or others disease which cannot be cured; lung disease,which cannot be cured, such as: destroyed lung, massive lung fabric; serious lung artery hypertession; intracranial hemorrhage; aged above 65 years; serious damage to central nervus system; MODS; forbidding to anti-coagulation therepy.

Design outcomes

Primary

Measure	Time frame
bleeding rate;tube aculsion rate;	—

Secondary

Measure	Time frame
frequency of heprin adjusting;patients survival rate;the dose of red blood cells used by patients;	—

Countries

China

Contacts

Public ContactRui Tian

Shanghai General Hospital

thunder021@hotmail.com+86 13764035999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026